Banque Transatlantique’s Axsome Therapeutics AXSM Stock Holding History

Banque Transatlantique’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.65M	Buy	+6,752	New	+$1.46M	0.04%	131

Other funds holding AXSM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

GIP

Granite Investment Partners El Segundo, California $1.95B AUM 49.89% 1-Year Est. Return

Banque Transatlantique's AXSM Position: Q2 2026 in Review

Banque Transatlantique opened a new position in Axsome Therapeutics (AXSM) in Q2 2026: 6,752 shares worth $1.65M. The stake represents 0.04% of the portfolio and ranks #131 among its holdings.

190 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

Banque Transatlantique held 6,752 shares of Axsome Therapeutics worth $1.65M as of Q2 2026.
Axsome Therapeutics was a new Banque Transatlantique position in Q2 2026.
Axsome Therapeutics made up 0.04% of Banque Transatlantique's portfolio in Q2 2026, its #131 holding.
190 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Banque Transatlantique's 13F filing for Q2 2026, filed 30 Jul 2026.